Table 1 Baseline characteristics
From: Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
N=32 | |
|---|---|
Median age, years (range) | 69 (52–82) |
Age ⩾75 years, n (%) | 8 (25%) |
Male, n (%) | 17 (53%) |
ISS disease stage at registration, n (%) | |
I | 11 (34%) |
II | 14 (44%) |
III | 7 (22%) |
MM subtype, n (%) | |
IgG | 23 (72%) |
IgA | 6 (19%) |
IgD | 2 (6%) |
Light chain | 1 (3%) |
Median creatinine clearance, ml/min (range) | 1 (0.5–1.9) |
Abnormal metaphase cytogenetics, n (%) | 10 (31%) |
FISH abnormalities, n (%) | |
del 13 | 2 (6%) |
del 17p | 4 (13%) |
t(4;4) | 0 |
t(14;6) | 0 |
t(11;14) | 9 (28%) |
Median number of therapies (range) | 2 (1–7) |
Bortezomib exposed, n (%) | 9 (28%) |
Lenalidomide refractory, n (%) | 25 (78%) |
Prior stem cell transplant, n (%) | 19 (60%) |
